Prevalence and cost of epilepsy in Sweden - a register-based approach

Acta Neurologica Scandinavica

Volumn 131, Issue 1, 2015, Pages 37-44

  Bolin, K ^a   Berggren, F ^b   Landtblom, A M ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UCB PHARMA   (Belgium)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cost of illness; Drug utilization; Epilepsy; Health economics

Indexed keywords

ADULT; AMBULATORY CARE; COST BENEFIT ANALYSIS; ECONOMICS; EPILEPSY; FEMALE; HEALTH CARE COST; HEALTH CARE DELIVERY; HOSPITALIZATION; HUMAN; PREVALENCE; REGISTER; STATISTICS AND NUMERICAL DATA; SWEDEN;

ADULT; AMBULATORY CARE; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; EPILEPSY; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; PREVALENCE; REGISTRIES; SWEDEN;

EID: 84920024054     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12297     Document Type: Article

References (25)

1. Liou HH, Chen RC, Chen CC, Chiu MJ, Chang YY, Wang JD. Health related quality of life in adult patients with epilepsy compared with a general reference population in Taiwan. Epilepsy Res 2005;64:151-9.
2. Trinka E, Bauer G, Oberaigner W, Ndayisaba JP, Seppi K, Granbichler CA. Cause-specific mortality among patients with epilepsy: results from a 30-year cohort study. Epilepsia 2013;54:495-501.
3. Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy - a systematic review. Pharmacoeconomics 2008;26:463-76.
4. Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007;48:2224-33.
5. Bolin K, Lundgren A, Berggren F, Källén K. Epilepsy in Sweden: healthcare costs and loss of productivity - a register-based approach. Eur J Health Econ 2012;13:819-26.
6. Silfvenius H. Economic costs of epilepsy - treatment benefits. Acta Neurol Scand Suppl 1988;117:136-54.
7. Persson PM, Russom A, Tomson T. Antiepileptic treatment nearly six times more expensive since 1990. Lakartidningen 2003;100:42-6.
8. Lindgren B. Costs of Illness in Sweden 1964-1975. Lund, Sweden: Lund University Economics Department, 1981 (diss).
9. Rice DP. Estimating the cost of illness. Health economic series no. 6. Public Health Service. Washington, DC: US Government Printing Office, 1966.
10. Poonam NB, Filippi D, Hausera A. The descriptive epidemiology of epilepsy - a review. Epilepsy Res 2009;85:31-45.
11. Giuliani G, Terziani S, Senigaglia AR, Luccioni G, Foschi N, Maffei C. Epilepsy in an Italian community as assessed by a survey for prescriptions of antiepileptic drugs: epidemiology and patterns of care. Acta Neurol Scand 1992;85:23-31.
12. National Board on Health and Welfare (Socialstyrelsen) Tillgång på vårdplatser (available hospital beds), 2010.
13. Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures - cost-utility results for Sweden. Acta Neurol Scand 2010;121:406-12.
14. Bolin K, Wachtmeister K, Stefan F, Forsgren L. Retigabine as add-on treatment of refractory epilepsy - a cost-utility study in a Swedish setting. Acta Neurol Scand 2013;127:419-26.
15. Swedish Epilepsy Association. Det räcker inte med kunskap om epilepsi - epilepsivården för vuxna ur ett kunskapsstyrnings- och patientperspektiv. 2009; http://epilepsi.se/ (accessed in may 2013).
16. Adelöw C. Epidemiological studies of epilepsy - incidence and risk factors. Stockholm, Sweden: Karolinska Institutet, 2011 (diss).
17. Forsgren L. Prevalence of epilepsy in adults in northern Sweden. Epilepsia 1992;33:450-8.
18. Keranen T, Riekkinen PJ, Sillanpää M. Incidence and prevalence of epilepsy in adults in eastern Finland. Epilepsia 1989;30:413-21.
19. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia 1991;32:429-45.
20. Beran RG, Michelazzi J, Hall L, Tsimnadis P, Loh S. False-negative response rate in epidemiologic studies to define prevalence ratios of epilepsy. Neuroepidemiology 1985;00:82-5.
21. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1996;61:433-43.
22. Jacoby A, Snape D, Baker GA. Epilepsy and social identity: the stigma of a chronic neurological disorder. Lancet Neurol 2005;4:171-8.
23. Ivanova JI, Birnbaum HG, Kidolezi Y et al. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia 2010;51:838-44.
24. Bolin K, Forsgren L. The cost effectiveness of newer treatments for partial-onset seizures - a review of the literature. Pharmacoeconomics 2012;30:903-23.
25. Johannessen Landmark C, Patsalos PN. Methodologies used to identify and characterize interactions among antiepileptic drugs. Expert Rev Clin Pharmacol, 2012;5:281-92.